Last reviewed · How we verify
Anti-PD1 armored CD19 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells) — Jiangsu Topcel-KH Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-PD1 armored CD19 CAR-T cells TARGET | Anti-PD1 armored CD19 CAR-T cells | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-PD1 armored CD19 CAR-T cells CI watch — RSS
- Anti-PD1 armored CD19 CAR-T cells CI watch — Atom
- Anti-PD1 armored CD19 CAR-T cells CI watch — JSON
- Anti-PD1 armored CD19 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). Anti-PD1 armored CD19 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-pd1-armored-cd19-car-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab